Buy Crysvita (burosumab) Online For Sale
From $3,107.00
Buy Waylivra (volanesorsen) Online For Sale
DISEASE INDICATIONS: Familial chylomicronemia syndrome (FCS)
MANUFACTURER: Akcea Therapeutics Ireland Limited
USAGE: Subcutaneous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Waylivra is a new RNA-targeted therapy that aims to inhibit the production of a protein that is key to fat metabolism, called ApoC-III, in order to lower triglyceride levels and reduce the associated health risks of familial chylomicronemia syndrome (FCS). Waylivra is administered by subcutaneous injection once a week, in conjunction with a low-fat diet and other lipid-lowering therapies as needed, and was approved by the US FDA in 2019.
Buy Palynziq (pegvaliase-pqpz) Online For Sale
DISEASE INDICATIONS: phenylketonuria (PKU)
MANUFACTURER: BioMarin Pharmaceutical Inc.
USAGE: Subcutaneous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Palynziq is an enzyme replacement therapy that has been developed for treating phenylketonuria (PKU), a genetic disorder that interferes with the body’s ability to break down phenylalanine. Palynziq introduces a modified version of the enzyme phenylalanine ammonia lyase (PAL) to break down phenylalanine and is administered as a subcutaneous injection on a daily basis.
Buy Crysvita (burosumab) Online For Sale
Crysvita is a medication used to treat X-linked hypophosphatemia (XLH), a rare genetic disease that causes low levels of phosphorus in the bloodstream, leading to symptoms such as stunted growth, weak bones, muscle weakness, and tooth defects. Crysvita is a monoclonal antibody that targets fibroblast growth factor 23 (FGF23), a hormone that regulates phosphorus and Vitamin D levels. Crysvita neutralizes FGF23, allowing phosphorus to be reabsorbed by the kidneys, correcting levels in the bloodstream. Crysvita has been found to be safe and effective, improving bone density and quality of life for patients. It is administered every two weeks as an injection. Crysvita is a significant and innovative treatment option for XLH patients.